Imunon (IMNN) Capital Expenditures (2010 - 2025)
Imunon's (IMNN) quarterly Capital Expenditures came in at $3589.0 in Q4 2025, down 75.92% YoY from $14907.0 in Q4 2024, and down 79.29% on a QoQ basis from $17331.0 in Q2 2025.
Imunon (IMNN) Capital Expenditures (2010 - 2025) Analysis & Trends
Imunon (IMNN) has 15 years of Capital Expenditures data on file, last reported at $3589.0 in Q4 2025.
- Quarterly Capital Expenditures fell 75.92% year-over-year to $3589.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $280572.0 (up 849.77% YoY) and the FY2025 annual result came in at $280572.0, up 849.77% from the prior year.
- Capital Expenditures slipped to $3589.0 in Q4 2025, from $17331.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $259652.0 in Q1 2025 to a low of $2879.0 in Q3 2024.
- A 5-year average of $78899.1 and a median of $56869.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures jumped 2733.78% — and 2024, when it tumbled 98.8%.
- Tracing IMNN's Capital Expenditures over 5 years: stood at $25642.0 in 2021, then surged by 75.14% to $44909.0 in 2022, then jumped by 435.19% to $240347.0 in 2023, then tumbled by 93.8% to $14907.0 in 2024, then plunged by 75.92% to $3589.0 in 2025.
- The last three Capital Expenditures figures came in at $3589.0 (Q4 2025), $17331.0 (Q2 2025), and $259652.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Imunon | 8.16 Mn | 8.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,589.00 |
| Dec 31, 2025 | 3,589.00 |
| Jun 30, 2025 | 17,331.00 |
| Jun 30, 2025 | 17,331.00 |
| Mar 31, 2025 | 259,652.00 |
| Mar 31, 2025 | 259,652.00 |
| Dec 31, 2024 | 14,907.00 |
| Dec 31, 2024 | 14,907.00 |
| Sep 30, 2024 | 2,879.00 |
| Sep 30, 2024 | 2,879.00 |
| Mar 31, 2024 | 11,755.00 |
| Mar 31, 2024 | 11,755.00 |
| Sep 30, 2023 | 240,347.00 |
| Sep 30, 2023 | 240,347.00 |
| Jun 30, 2023 | 154,270.00 |
| Jun 30, 2023 | 154,270.00 |
| Mar 31, 2023 | 57,142.00 |
| Mar 31, 2023 | 57,142.00 |
| Dec 31, 2022 | 44,909.00 |
| Dec 31, 2022 | 44,909.00 |